戻る
「早戻しボタン」を押すと検索画面に戻ります。

今後説明を表示しない

[OK]

コーパス検索結果 (1語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 uman ARL15 haploinsufficiency predisposes to lipodystrophy.
2  whereby pathogenic mutations in BSCL2 cause lipodystrophy.
3  respect to dyslipidemia, hyperglycemia, and lipodystrophy.
4 otypes, providing a mouse model of inducible lipodystrophy.
5  fat have a phenotype reminiscent of partial lipodystrophy.
6  short-term overfeeding in patients with HIV lipodystrophy.
7 hy, or later in life, as in familial partial lipodystrophy.
8 cations for anti-obesity medical therapy and lipodystrophy.
9 iabetes, obesity, cancer, and HIV-associated lipodystrophy.
10 zed by dyslipidemia, insulin resistance, and lipodystrophy.
11 sed levels of IGF-1 in HIV-infected men with lipodystrophy.
12  men with human immunodeficiency virus (HIV) lipodystrophy.
13 sociated with better lipid profiles and less lipodystrophy.
14 cles, acro-osteolysis, cutaneous atrophy and lipodystrophy.
15 ked to the insulin resistance of obesity and lipodystrophy.
16 en reported in patients with MAD and partial lipodystrophy.
17 ed with progeroid appearance and generalized lipodystrophy.
18 ssociated hepatic steatosis in patients with lipodystrophy.
19 tutively low leptin levels, such as occur in lipodystrophy.
20 tabolic abnormalities associated with severe lipodystrophy.
21 ment, and provide a candidate gene for human lipodystrophy.
22 isk parameters in HIV-infected patients with lipodystrophy.
23      None of the subjects exhibited clinical lipodystrophy.
24  lipodystrophy, Berardinelli-Seip congenital lipodystrophy.
25       This may explain WZB117-induced murine lipodystrophy.
26 cells from progeroid INK-ATTAC mice prevents lipodystrophy.
27  have therapeutic applications in obesity or lipodystrophy.
28 , an aged appearance, and severe generalized lipodystrophy.
29 al link between this process and HIV-related lipodystrophy.
30 ile consistent with a common, subtle form of lipodystrophy.
31 se ob/ob background accelerated the onset of lipodystrophy.
32 ribe a family with MPGN and acquired partial lipodystrophy.
33 describe here a unique mouse model of severe lipodystrophy.
34 in-resistant patients with hyperglycemia and lipodystrophy.
35 ies that have been utilized in patients with lipodystrophy.
36 enesis and maintenance and the cause of some lipodystrophies.
37 sms underlying dyslipidemia in patients with lipodystrophies.
38 2), have been found in patients with genetic lipodystrophies.
39 nt of fat loss also varies among subtypes of lipodystrophies.
40 of body fat is the hallmark of patients with lipodystrophies.
41 K2) could also be a candidate gene for other lipodystrophies.
42 dating the molecular basis of many inherited lipodystrophies.
43 ltransferase 2, Berardinelli-Seip congenital lipodystrophy 2, caveolin 1, lamin A/C, peroxisome proli
44 dystrophy (8 patients) or Dunnigan's partial lipodystrophy (2 patients) were included in this analysi
45 as significantly higher in patients with HIV lipodystrophy [33.2 +/- 0.27 kcal/kg lean body mass (LBM
46         Ten patients with either generalized lipodystrophy (8 patients) or Dunnigan's partial lipodys
47 tin is an approved treatment for generalized lipodystrophy, a condition associated with severe metabo
48                                  People with lipodystrophy, a disorder characterized by particularly
49  dystrophy (fld) gene have features of human lipodystrophy, a genetically heterogeneous group of diso
50 ncoding lamin A/C) underlie familial partial lipodystrophy, a syndrome of monogenic insulin resistanc
51            In contrast, in monogenic primary lipodystrophy-a reduction in subcutaneous adipose tissue
52 of autosomal recessive and dominant types of lipodystrophies and therapeutic interventions available
53 lice site mutation in a proband with partial lipodystrophy and a history of childhood yolk sac tumour
54 ity and type 2 diabetes mellitus, as well as lipodystrophy and aging.
55 ouse model (fatless AZIP/F-1 mice) of severe lipodystrophy and diabetes.
56 y associated with metabolic diseases such as lipodystrophy and diabetes.
57 hronic atypical neutrophilic dermatosis with lipodystrophy and elevated temperature (CANDLE syndrome)
58 hronic atypical neutrophilic dermatosis with lipodystrophy and elevated temperature (CANDLE), which i
59 nant-negative mutations in PPARgamma display lipodystrophy and extreme insulin resistance.
60  1 in the mouse, but not in humans, leads to lipodystrophy and fatty liver disease.
61  dystrophy (fld) mice, which exhibit partial lipodystrophy and have diminished peripheral adipose sto
62 protease inhibitor therapy adversely induces lipodystrophy and hyperlipidemia has not been defined.
63 ceiving protease inhibitors develop a marked lipodystrophy and hyperlipidemia.
64  example, mutations in PPARG cause Mendelian lipodystrophy and increase risk of type 2 diabetes (T2D)
65 , making the A-ZIP/F-1 mice a good model for lipodystrophy and insulin resistance.
66 aneously by 1 year of age, despite sustained lipodystrophy and insulin resistance.
67 tions in PPARG are known to cosegregate with lipodystrophy and insulin resistance; in the general pop
68         PPARgamma inactivation caused severe lipodystrophy and insulin resistance; surprisingly, it a
69 re of human and rodent models of generalized lipodystrophy and is also a common feature of type 2 dia
70 ides a conditional animal model for studying lipodystrophy and its associated physiology and gene exp
71 creased triglyceride levels in patients with lipodystrophy and leptin deficiency.
72 ytes undergo dedifferentiation that leads to lipodystrophy and metabolic dysfunction.
73 with adverse side effects, including partial lipodystrophy and metabolic syndrome.
74 lethal combination of pathologies, including lipodystrophy and multiple hemorrhages.
75 nse mutation in a proband with femorogluteal lipodystrophy and non classical congenital adrenal hyper
76                                              Lipodystrophy and obesity are opposites in terms of a de
77 ed that adipose tissue macrophages (ATMs) in lipodystrophy and obesity are very different in terms of
78 s an accumulation of prelamin A and leads to lipodystrophy and other disease phenotypes.
79                                          HIV lipodystrophy and other lipodystrophy syndromes are char
80 atment for HIV but have been associated with lipodystrophy and other side effects.
81 o suggest and prioritize candidate genes for lipodystrophy and related disorders.
82 years; eight with diabetes mellitus) who had lipodystrophy and serum leptin levels of less than 4 ng
83  monogenic diabetic syndromes and congenital lipodystrophies, and candidate gene association studies
84 lude muscular dystrophies, cardiomyopathies, lipodystrophies, and premature aging syndromes.
85 ulin resistance in obesity, type 2 diabetes, lipodystrophy, and ageing; and the insulin-sensitising e
86 ders, including obesity, metabolic syndrome, lipodystrophy, and cachexia.
87 rder characterized by short stature, partial lipodystrophy, and insulin resistance.
88 including markedly aberrant fuel metabolism, lipodystrophy, and muscular dystrophy.
89 ee genetic diseases: HVDRR, congenital total lipodystrophy, and persistent mullerian duct syndrome.
90 g, obesity, Cushing's syndrome, and acquired lipodystrophy, and preliminary evidence suggests that ec
91 ncluding muscular dystrophy, cardiomyopathy, lipodystrophy, and progeria, but mutations in B-type lam
92 uman diseases, including muscular dystrophy, lipodystrophy, and progeria, but no diseases have been l
93  muscular dystrophy, cardiomyopathy, partial lipodystrophy, and progeroid syndromes.
94  muscular dystrophy, cardiomyopathy, partial lipodystrophy, and progeroid syndromes.
95 (-/-) mice were lean, demonstrated abdominal lipodystrophy, and remained insulin-sensitive despite ha
96 es, which include premature aging syndromes, lipodystrophy, and striated muscle disorders.
97 reduction in body weight and length, partial lipodystrophy, and systemic insulin resistance.
98 most cases of NAFLD associated with obesity, lipodystrophy, and type 2 diabetes.
99                                 In contrast, lipodystrophy (aP2-SREBP-1c436) and liver X receptor act
100                      In this population, the lipodystrophy appears to be a direct consequence of drug
101                                          The lipodystrophies are a group of disorders characterized b
102                                    Inherited lipodystrophies are an important cause for monogenic hyp
103                                              Lipodystrophies are characterized by a loss of white adi
104                                    Inherited lipodystrophies are rare autosomal recessive and dominan
105                                              Lipodystrophies are rare inherited and acquired disorder
106                                              Lipodystrophies are syndromes of adipose tissue degenera
107 ein cholesterol, higher body-mass index, and lipodystrophy are potentially modifiable risk factors as
108                             Panniculitis and lipodystrophy are rare disorders of subcutaneous tissue.
109 podystrophy was hypertensive, ruling out the lipodystrophy as a cause.
110 A cause laminopathies, which include partial lipodystrophies associated with metabolic syndromes.
111 2) describe a stereotyped pattern of partial lipodystrophy associated with all the features of the me
112 L) type 2 (BSCL2; also known as seipin) is a lipodystrophy-associated endoplasmic reticulum membrane
113 ling agents as a potential novel therapy for lipodystrophy-associated hypertriglyceridemia, NASH and
114                                          The lipodystrophy-associated LMNA p.R482W mutation is known
115     These findings distinguish myopathy- and lipodystrophy-associated mutations and provide a structu
116             Skin analyses in other models of lipodystrophy, AZIP(tg/+) and Adipoq-Cre(tg/+)Pparg(fl/f
117                    A case definition for HIV lipodystrophy, based on age, gender, duration of HIV dis
118 sis, suggesting that neither strain develops lipodystrophy because of defective adipocyte differentia
119  the most common form of autosomal recessive lipodystrophy, Berardinelli-Seip congenital lipodystroph
120  the context of Berardinelli-Seip congenital lipodystrophy (BSCL) linked to seipin deficiency.
121                 Berardinelli-Seip congenital lipodystrophy (BSCL) type 2 (BSCL2; also known as seipin
122 increased significantly in patients with HIV lipodystrophy but not in the control groups (33.2 +/- 0.
123 improving metabolic control in patients with lipodystrophy, but its efficacy has not been tested in o
124  obesity, type 2 diabetes, and some forms of lipodystrophy, but whether this dysfunction contributes
125 s in AGPAT2 may cause congenital generalized lipodystrophy by inhibiting triacylglycerol synthesis an
126  be attuned to the psychological impact that lipodystrophy can have on patients, especially because i
127 estimating the pathogenesis of human partial lipodystrophy caused by CIDEC mutations.
128                       Congenital generalized lipodystrophy (CGL) is a rare autosomal recessive disord
129                       Congenital generalized lipodystrophy (CGL) is a rare disorder characterized by
130 ny of the features of congenital generalized lipodystrophy (CGL), an autosomal recessive disorder in
131                       Congenital generalized lipodystrophy (CGL), secondary to AGPAT2 mutation is cha
132 viduals affected with congenital generalized lipodystrophy (CGL).
133                                A syndrome of lipodystrophy, characterized by fat redistribution and i
134                The familial partial Dunnigan lipodystrophy, characterized by subcutaneous fat loss, i
135 f fatty liver disease using a mouse model of lipodystrophy created by a fat-specific knockout of the
136 an association with calcinosis and p155 with lipodystrophy), cytokine polymorphisms, which appear to
137 tisystem disorder that includes subcutaneous lipodystrophy, deafness, mandibular hypoplasia and hypog
138 nts with a novel subtype of familial partial lipodystrophy, designated as FPLD4.
139 tant regulator of metabolism associated with lipodystrophy, diabetes, and hepatic steatosis.
140                    These mice develop severe lipodystrophy, diabetes, hyperlipidemia, and fatty liver
141                             Familial partial lipodystrophy, Dunnigan variety, (FPLD, OMIM 308980) is
142               Metabolic disorders, including lipodystrophy, dyslipidemia, and insulin resistance, occ
143                                Patients with lipodystrophy exhibit hypertriglyceridemia, severe insul
144 yme Dicer (ADicerKO), as well as humans with lipodystrophy, exhibit a substantial decrease in levels
145 , fat samples from patients with HIV-related lipodystrophy exhibited a substantial downregulation of
146                                Among genetic lipodystrophies, fat loss is observed either from birth,
147                      Lipin deficiency causes lipodystrophy, fatty liver, and insulin resistance in mi
148                             Familial partial lipodystrophy (FPLD), Dunnigan variety, is an autosomal
149 cle defects, and the other, familial partial lipodystrophy (FPLD), involves loss of subcutaneous adip
150 dystrophy and Dunnigan-type familial partial lipodystrophy (FPLD).
151 s of muscular dystrophy and familial partial lipodystrophy (FPLD).
152 idues genetically linked to familial partial lipodystrophy (FPLD).
153  understanding of the biologic role of these lipodystrophy genes.
154  The term 'HIV/HAART associated dyslipidemic lipodystrophy (HADL)' describes this syndrome.
155                    Recently the incidence of lipodystrophy has been increasing secondary to its appea
156 netic studies in hyperglycemic patients with lipodystrophies have revealed accelerated lipolysis and
157 scribe a metabolic disorder characterized by lipodystrophy, hepatic steatosis, insulin resistance, se
158 ed with several metabolic changes, including lipodystrophy, hyperlipidemia, and insulin resistance.
159 metabolic side effects, including peripheral lipodystrophy, hyperlipidemia, insulin resistance, and i
160 ndrome that resembles congenital generalized lipodystrophy in humans.
161 d adipocyte differentiation as the basis for lipodystrophy in lipin-deficient mice and demonstrate th
162                      Lipin-1 mutations cause lipodystrophy in mice and acute myopathy in humans.
163 ted allele that confers conditional dominant lipodystrophy in mice.
164 ents to treat the different features seen in lipodystrophy in order to reduce their long-term cardiov
165                         The apparent partial lipodystrophy in Reep1 null mice, although less severe,
166         Both physician and patient rating of lipodystrophy in the arms, legs, and abdomen also improv
167 the Lpin1 (lipin) gene to be responsible for lipodystrophy in the fatty liver dystrophy (fld) mouse s
168 ns in the lipin gene, Lpin1, as the cause of lipodystrophy in the fatty liver dystrophy (fld) mouse.
169 encoding lipin-1, as the underlying cause of lipodystrophy in the fatty liver dystrophy (fld) mutant
170 nzymes and explain the biochemical basis for lipodystrophy in the lipin-1-deficient fld mouse.
171 ia, and panniculitis-induced childhood-onset lipodystrophy) in adults.
172 sulin resistance, but their contributions to lipodystrophy-induced insulin resistance have not been e
173               Unexpectedly, tTA elicits mild lipodystrophy, insulin resistance, and dyslipidemia, and
174                                              Lipodystrophy is a disorder characterized by a loss of a
175                                              Lipodystrophy is a rare disorder characterized by comple
176                                              Lipodystrophy is a rare disorder that is characterized b
177                       Congenital generalized lipodystrophy is an autosomal recessive disorder charact
178                                 Since severe lipodystrophy is associated with leptin deficiency, insu
179                            Berardinelli-Seip lipodystrophy is caused by autosomal recessive mutations
180                                       Severe lipodystrophy is characterized by diminished adipose tis
181                                              Lipodystrophy is characterized by the complete or partia
182 hown in family members with acquired partial lipodystrophy, it did not segregate with the renal pheno
183  microcytic anemia, and panniculitis-induced lipodystrophy (JMP).
184                                              Lipodystrophy (LD) is a rare disease with a paucity of s
185 cted individuals may develop malnutrition or lipodystrophy, leading to losses of subcutaneous adipose
186 patients with extreme insulin resistance and lipodystrophy, leptin ameliorates insulin resistance, hy
187 white and brown adipose tissue resulted in a lipodystrophy-like syndrome.
188 noted were hepatitis, peripheral neuropathy, lipodystrophy/lipoatrophy, and pancreatitis, whereas the
189 us, raising the possibility of more than two lipodystrophy loci within the Oman population.
190 encoding proteins known to activate lipin, a lipodystrophy locus in mice, and 16 other genes that are
191        Lipin 2 (LPIN2), a candidate gene for lipodystrophy, maps in proximity to this locus.
192 y of dyslipidemia in these rare disorders of lipodystrophies may offer insights into the normal role
193 ther research is needed to determine whether lipodystrophy may be misdiagnosed as wasting syndrome.
194 lipidemia, insulin resistance, hypoglycemia, lipodystrophy, motor-neuron death, and hepatitis C infec
195 orders of liporegulation include generalized lipodystrophies, mutations of leptin and leptin receptor
196 E was measured in HIV-infected patients with lipodystrophy (n = 9) and in HIV-infected (n = 10) and h
197 ange of human disorders, including progeria, lipodystrophy, neuropathies and autosomal dominant Emery
198 ose tissue, and adipocyte dysfunction causes lipodystrophy, obesity and diabetes.
199 ts in the context of human linkage scans for lipodystrophy, obesity, and type 2 diabetes.
200  FIT2 (AF2KO) in mice results in progressive lipodystrophy of white adipose depots and metabolic dysf
201 ons cause axonal neuropathy, with associated lipodystrophy only occasionally noted, however homozygos
202                                              Lipodystrophy or fat re-distribution, and its associated
203 CI, 1.13-1.49]; P<.001), and the presence of lipodystrophy (OR, 3.82 [95% CI, 1.13-12.88]; P=.03).
204                 In mice with too little fat (lipodystrophy) or too much fat (ob/ob), leptin deficienc
205 issense mutation in human seipin that causes lipodystrophy, or corresponding mutations in the yeast g
206 her from birth, as in congenital generalized lipodystrophy, or later in life, as in familial partial
207 riptional role of PTRF not only explains the lipodystrophy phenotype observed in PTRF deficient mice
208                                      Partial lipodystrophy (PLD; MIM 151660) is an inherited conditio
209                                          The lipodystrophy protein SEIPIN is important for lipid drop
210             The prevalence of HIV-associated lipodystrophy ranges from 6% to 69% in the medical liter
211 -ray absorptiometry and computed tomography, lipodystrophy ratings, and levels of glucose, insulin, a
212 uman immunodeficiency virus (HIV)-associated lipodystrophy refers to fat accumulation, also known as
213 iver is a common feature of both obesity and lipodystrophy, reflecting compromised adipose tissue fun
214                   Loss of adipose tissue, or lipodystrophy, results in hyperinsulinemia, diabetes mel
215 d with a similar phenotype including partial lipodystrophy, severe insulin resistance and type 2 diab
216                       Both patients also had lipodystrophy, severe insulin resistance, and diabetes,
217                                          HIV lipodystrophy syndrome (HLS) is characterized by acceler
218 lycerolemia, a characteristic feature of HIV lipodystrophy syndrome (HLS), is incompletely understood
219 tprandial period may be a feature of the HIV lipodystrophy syndrome and may be due to an inability to
220 ether these changes have been termed the HIV-lipodystrophy syndrome, which is estimated to affect a m
221 e metabolic disturbances associated with HIV lipodystrophy syndrome.
222                                              Lipodystrophy syndromes are also associated with increas
223                  HIV lipodystrophy and other lipodystrophy syndromes are characterized by extensive l
224 or 1 have been described linked to different lipodystrophy syndromes.
225 but tended to be higher in patients with HIV lipodystrophy than in healthy controls after a large tes
226      Although ATMs are even more abundant in lipodystrophy than in obesity, they have distinct phenot
227 iew addresses a syndrome of dyslipidemia and lipodystrophy that has emerged in HIV-infected patients
228 a fat-specific KO of dicer develop a form of lipodystrophy that is characterized by loss of intra-abd
229  drug-induced liver injury and depression or lipodystrophy) that led to discontinuation.
230 ct insulin sensitivity, as observed in human lipodystrophy, through reduced levels of adipocyte-deriv
231 signaling in a diabetic model of generalized lipodystrophy to analyze its effects on glucose metaboli
232 ransgenic (Tg) mice, an established model of lipodystrophy, to ask this question.
233 a polygenic contribution to familial partial lipodystrophy type 1, a severe form of insulin resistanc
234                 Berardinelli-Seip congenital lipodystrophy type 2 (BSCL2) is a recessive disorder fea
235 herited form is Berardinelli-Seip Congenital Lipodystrophy Type 2, associated with mutations in the B
236 reserved in mice with congenital generalized lipodystrophy type 3.
237 T occurs in mice with congenital generalized lipodystrophy type 4, whereas both rMAT and cMAT are pre
238        We showed that another mouse model of lipodystrophy was hypertensive, ruling out the lipodystr
239                        Investigator-reported lipodystrophy was less common in the tenofovir DF group
240                     Clinical and subclinical lipodystrophy was not noted in those younger than 5 year
241                 However, fat redistribution (lipodystrophy) was recognized recently as a metabolic si
242 ight into how altered AGPAT2 activity causes lipodystrophy, we examined the effect of knockdown of AG
243 arboring pathogenic mutations known to cause lipodystrophy were also generated and characterized.
244 -1c mice develop a syndrome resembling human lipodystrophy, which includes a loss of peripheral white
245  Mr B, a 39-year-old man with HIV-associated lipodystrophy whose facial changes are a cause of signif
246                Efforts to ameliorate NASH in lipodystrophies with pharmacologic agents have met with
247 ion in adipose tissue can lead a syndrome of lipodystrophy with metabolic syndrome and cardiovascular
248 phy (fld) mouse is an exception, as there is lipodystrophy without a fatty liver.

WebLSDに未収録の専門用語(用法)は "新規対訳" から投稿できます。
 
Page Top